This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| gamma‑glutamyl carboxylase | |
|---|---|
| Name | gamma‑glutamyl carboxylase |
| Ec number | 4.1.1.90 |
| Other names | vitamin K‑dependent carboxylase |
| Gene | GGCX |
gamma‑glutamyl carboxylase is an enzyme responsible for post‑translational modification of specific proteins by converting glutamate residues to gamma‑carboxyglutamate (Gla), a reaction essential for the activity of several coagulation cascade factors and extracellular matrix proteins. It operates in the endoplasmic reticulum and requires reduced vitamin K as a cofactor, linking it functionally to therapies and policies involving warfarin, anticoagulant management, and public health guidance from agencies such as the World Health Organization and national Food and Drug Administration. The enzyme is encoded by the human GGCX gene and has been studied across clinical genetics, biochemistry, and evolutionary biology by institutions including Harvard University, University of Cambridge, and the National Institutes of Health.
Gamma‑glutamyl carboxylase catalyzes carboxylation of glutamate side chains to produce Gla residues in vitamin K‑dependent proteins such as clotting factors II, VII, IX, and X, and regulatory proteins like protein C and protein S, which are central to the coagulation cascade, hemostasis, and thrombotic disorders tracked by organizations such as the American Heart Association and European Society of Cardiology. The enzyme couples oxidative vitamin K recycling with carbon dioxide incorporation, a biochemical process that intersects with cellular pathways studied at centers like the Max Planck Society and influenced therapeutic decisions made at hospitals including Mayo Clinic and Cleveland Clinic. Loss of carboxylation impairs calcium binding in Gla domains, altering interactions with membranes, receptors, and components of the extracellular matrix, an effect evaluated in clinical trials registered through agencies such as the National Library of Medicine.
The protein is an integral membrane enzyme of the endoplasmic reticulum with multiple transmembrane segments, elucidated by structural biology groups at institutions like European Molecular Biology Laboratory and Scripps Research. Mechanistic studies show a coupling between vitamin K epoxide reduction and carboxylation, implicating conserved residues and histidine/glutamate catalytic motifs characterized in comparative analyses by laboratories such as Cold Spring Harbor Laboratory and Johns Hopkins University. High‑resolution approaches, including cryo‑electron microscopy and mutational mapping performed in collaborations with facilities like the European Synchrotron Radiation Facility and Brookhaven National Laboratory, have identified substrate recognition sites that position glutamate residues for CO2 addition and calcium coordination essential for Gla domain folding.
The human GGCX gene is located on chromosome 2 and has been the subject of linkage and association studies conducted by consortia including the International HapMap Project and the 1000 Genomes Project, with notable variants linked to altered enzyme activity and clinical phenotypes in cohorts recruited by universities such as Stanford University and University College London. Transcriptional and post‑translational regulation involves endoplasmic reticulum quality control pathways researched at institutes including the European Bioinformatics Institute and the Broad Institute, and is modulated by cellular vitamin K status and interactions with vitamin K epoxide reductase components characterized in pharmacogenomic studies involving the Pharmacogenomics Research Network.
Mutations in GGCX cause bleeding disorders, combined deficiency of vitamin K‑dependent clotting factors, and calcification phenotypes documented in case series from tertiary centers like Great Ormond Street Hospital and Boston Children's Hospital. Altered carboxylase activity influences responsiveness to oral anticoagulants such as warfarin and has implications for personalized medicine approaches advocated by organizations such as the American College of Medical Genetics and Genomics. Associations have also been reported between impaired carboxylation and vascular calcification, pseudoxanthoma elasticum‑like syndromes, and bone mineral density variations investigated in population studies by teams at Karolinska Institutet and the University of Oxford.
The enzyme requires reduced vitamin K (vitamin K hydroquinone) and couples with vitamin K epoxide reductase complex proteins which are targets of warfarin and related coumarin anticoagulants developed and regulated in part by pharmaceutical companies and health agencies such as the European Medicines Agency. It acts on substrates possessing the Gla domain motif found in proteins characterized by laboratories at Massachusetts Institute of Technology and the University of California, San Francisco, and its activity is influenced by calcium ions and endoplasmic reticulum chaperones including pathways dissected at institutions like Yale University and University of Pennsylvania.
Gamma‑glutamyl carboxylase is conserved across metazoans, with homologs identified in vertebrate model organisms such as Mus musculus, Danio rerio, and Xenopus laevis, and more divergent homologs in invertebrates explored by evolutionary biologists at museums and universities including the Natural History Museum, London and Smithsonian Institution. Comparative genomics projects such as Ensembl and GenBank document sequence conservation of catalytic residues, supporting evolutionary analyses conducted by groups at the University of California, Berkeley and the Max Planck Institute for Evolutionary Anthropology that map the emergence of vitamin K‑dependent carboxylation to early multicellular lineages.
Category:Enzymes Category:Vitamin K